Emergent BioSolutions, Inc., looks to expand

Emergent BioSolutions, Inc., the makers of the only FDA-approved anthrax vaccine, are making plans to expand beyond the realm of biodefense.

Emergent BioSolutions, Inc., executives said that they intend to remain competitive by expanding the number and variety of drugs that they currently have on the market. according to the Washington Post.

“We can start to move outside the biodefense realm and into more commercial segments,” Kyle Keese, senior vice-president for manufacturing operations at Emergent BioSolutions, Inc.,, told the Washington Post.

Emergent BioSolutions, Inc., Chief Executive Officer Fuad El-Hibri told the Washington Post that the newly opened Baltimore facility will allow the company to take on more government work, as well as break into the commercial sector. Emergent BioSolutions, Inc., is currently testing vaccines for typhoid and tuberculosis.

At the center of these plans is a 55,000 square foot facility undergoing renovations in Baltimore. On July 16, Maryland Governor Martin O’Malley appeared for the facility’s ribbon cutting ceremony and lauded the company for investing in Maryland jobs and Maryland science.

Over the next five years, about 120 jobs are expected to be created at the facility and a further $30 million will be spent preparing it for use. Purchased from an existing MdBio lab facility, Emergent BioSolutions, Inc., intends to take the five previous laboratories and combine them into two - one to manufacture viral vaccines and the other non-viral vaccines. The company may look to a neighboring lot if these plans are not sufficient.